Progress in the initial management of Hodgkin's Lymphoma

Preethi R. Marri, Stephen Maxted Ansell

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Hodgkin lymphoma (HL) is an uncommon B-cell lymphoid malignancy composed of two distinct disease entities; the more commonly diagnosed classical HL and the rare nodular lymphocyte predominant HL. Nodular sclerosis, mixed cellularity, lymphocyte depletion, and lymphocyte-rich HL are subgroups under the designation of classical HL. An accurate assessment of the stage of disease in patients with HL is critical for the selection of appropriate therapy. Prognostic models that identify patients at low or high risk for recurrence are used to optimize therapy for patients with limited or advanced stage disease and predict their outcomes while reducing the toxicities. Initial therapy for HL patients is based on the histology, anatomical stage and the presence of poor prognostic features. Management of localized HL has shifted from radiation alone to combined modality strategies with brief courses of combination chemotherapy followed by involved-field radiation therapy. Patients with advanced stage disease receive a longer course of chemotherapy commonly without radiation therapy. Clinical trials are being conducted using the early interim response or response at the end of therapy as measured by PET scan to determine treatment.

Original languageEnglish (US)
Pages (from-to)12-18
Number of pages7
JournalTransfusion and Apheresis Science
Volume49
Issue number1
DOIs
StatePublished - Aug 2013

Fingerprint

Hodgkin Disease
Radiotherapy
Lymphocyte Depletion
Therapeutics
Sclerosis
Combination Drug Therapy
Positron-Emission Tomography
Histology
B-Lymphocytes
Clinical Trials
Lymphocytes
Radiation
Recurrence
Drug Therapy
Neoplasms

Keywords

  • Advanced disease
  • Combined therapy
  • Hodgkin lymphoma
  • Limited stage
  • Prognostic factors

ASJC Scopus subject areas

  • Hematology

Cite this

Progress in the initial management of Hodgkin's Lymphoma. / Marri, Preethi R.; Ansell, Stephen Maxted.

In: Transfusion and Apheresis Science, Vol. 49, No. 1, 08.2013, p. 12-18.

Research output: Contribution to journalArticle

@article{b6e1c57d12b647da9cfaf0116d49d221,
title = "Progress in the initial management of Hodgkin's Lymphoma",
abstract = "Hodgkin lymphoma (HL) is an uncommon B-cell lymphoid malignancy composed of two distinct disease entities; the more commonly diagnosed classical HL and the rare nodular lymphocyte predominant HL. Nodular sclerosis, mixed cellularity, lymphocyte depletion, and lymphocyte-rich HL are subgroups under the designation of classical HL. An accurate assessment of the stage of disease in patients with HL is critical for the selection of appropriate therapy. Prognostic models that identify patients at low or high risk for recurrence are used to optimize therapy for patients with limited or advanced stage disease and predict their outcomes while reducing the toxicities. Initial therapy for HL patients is based on the histology, anatomical stage and the presence of poor prognostic features. Management of localized HL has shifted from radiation alone to combined modality strategies with brief courses of combination chemotherapy followed by involved-field radiation therapy. Patients with advanced stage disease receive a longer course of chemotherapy commonly without radiation therapy. Clinical trials are being conducted using the early interim response or response at the end of therapy as measured by PET scan to determine treatment.",
keywords = "Advanced disease, Combined therapy, Hodgkin lymphoma, Limited stage, Prognostic factors",
author = "Marri, {Preethi R.} and Ansell, {Stephen Maxted}",
year = "2013",
month = "8",
doi = "10.1016/j.transci.2013.05.018",
language = "English (US)",
volume = "49",
pages = "12--18",
journal = "Transfusion and Apheresis Science",
issn = "1473-0502",
publisher = "Elsevier Limited",
number = "1",

}

TY - JOUR

T1 - Progress in the initial management of Hodgkin's Lymphoma

AU - Marri, Preethi R.

AU - Ansell, Stephen Maxted

PY - 2013/8

Y1 - 2013/8

N2 - Hodgkin lymphoma (HL) is an uncommon B-cell lymphoid malignancy composed of two distinct disease entities; the more commonly diagnosed classical HL and the rare nodular lymphocyte predominant HL. Nodular sclerosis, mixed cellularity, lymphocyte depletion, and lymphocyte-rich HL are subgroups under the designation of classical HL. An accurate assessment of the stage of disease in patients with HL is critical for the selection of appropriate therapy. Prognostic models that identify patients at low or high risk for recurrence are used to optimize therapy for patients with limited or advanced stage disease and predict their outcomes while reducing the toxicities. Initial therapy for HL patients is based on the histology, anatomical stage and the presence of poor prognostic features. Management of localized HL has shifted from radiation alone to combined modality strategies with brief courses of combination chemotherapy followed by involved-field radiation therapy. Patients with advanced stage disease receive a longer course of chemotherapy commonly without radiation therapy. Clinical trials are being conducted using the early interim response or response at the end of therapy as measured by PET scan to determine treatment.

AB - Hodgkin lymphoma (HL) is an uncommon B-cell lymphoid malignancy composed of two distinct disease entities; the more commonly diagnosed classical HL and the rare nodular lymphocyte predominant HL. Nodular sclerosis, mixed cellularity, lymphocyte depletion, and lymphocyte-rich HL are subgroups under the designation of classical HL. An accurate assessment of the stage of disease in patients with HL is critical for the selection of appropriate therapy. Prognostic models that identify patients at low or high risk for recurrence are used to optimize therapy for patients with limited or advanced stage disease and predict their outcomes while reducing the toxicities. Initial therapy for HL patients is based on the histology, anatomical stage and the presence of poor prognostic features. Management of localized HL has shifted from radiation alone to combined modality strategies with brief courses of combination chemotherapy followed by involved-field radiation therapy. Patients with advanced stage disease receive a longer course of chemotherapy commonly without radiation therapy. Clinical trials are being conducted using the early interim response or response at the end of therapy as measured by PET scan to determine treatment.

KW - Advanced disease

KW - Combined therapy

KW - Hodgkin lymphoma

KW - Limited stage

KW - Prognostic factors

UR - http://www.scopus.com/inward/record.url?scp=84882869048&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84882869048&partnerID=8YFLogxK

U2 - 10.1016/j.transci.2013.05.018

DO - 10.1016/j.transci.2013.05.018

M3 - Article

C2 - 23769695

AN - SCOPUS:84882869048

VL - 49

SP - 12

EP - 18

JO - Transfusion and Apheresis Science

JF - Transfusion and Apheresis Science

SN - 1473-0502

IS - 1

ER -